Nam, J S; Kim, A R; Yoon, J C; Byun, Y; Kim, S A; Kim, K R; Cho, S; Seong, B L; Ahn, C W; Lee, J M
Diabetic medicine : a journal of the British Diabetic Association
2011Jul ; 28 ( 7 ) :815-7.
PMID : 21672004
ÀúÀÚ »ó¼¼Á¤º¸
Nam, J S -
Kim, A R -
Yoon, J C -
Byun, Y -
Kim, S A -
Kim, K R -
Cho, S -
Seong, B L -
Ahn, C W -
Lee, J M -
ABSTRACT
AIMS: We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses.
METHODS: Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA.
RESULTS: Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate.
CONCLUSIONS: Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination. CI - ??2011 The Authors. Diabetic Medicine ??2011 Diabetes UK.
antibody seroconversion, influenza A (H1N1) 2009 monovalent vaccine, Type 2 diabetes mellitus
MESH
Adolescent, Adult, Aged, Antibodies, Viral/immunology, Antibody Formation/immunology, Diabetes Mellitus, Type 2/complications/epidemiology/*immunology, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunity, Humoral, Influenza A Virus, H1N1 Subtype/*immunology, Influenza Vaccines/*immunology, Influenza, Human/epidemiology/*prevention & control, Korea/epidemiology, Male, Middle Aged, Risk Factors, Young Adult
¸µÅ©